Shionogi & Co. Ltd. (4507.TO) Osaka 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y99.78 bln Y97.59 bln Operating Profit Y35.10 bln Y28.11 bln Pretax Profit Y46.33 bln Y36.53 bln Net Profit Y39.36 ...

Shionogi & Co ( ($SGIOF) ) has released its Q1 earnings. Here is a breakdown of the information Shionogi & Co presented to its investors. Shionogi ...

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of ...

Wastewater surveillance at treatment plants offers a low-cost, early warning method for detecting COVID-19. Researchers in Japan conducted an economic evaluation of a system for long-term care ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust ...

Japanese Shionogi came on board last year, paying $100 million upfront to license European and Asian rights to the drug, with F2G retaining rights in North America.

Shionogi & Co. Ltd. ADR annual income statement. View SGIOY financial statements in full, including balance sheets and ratios.

Get the annual and quarterly balance sheet of Shionogi & Co., Ltd. (4507.T) including details of assets, liabilities and shareholders' equity.

Aspergillus fumigatus is developing greater resistance to its first-line treatment, and many patients are infected with ...

Also on Trump’s mind is the Federal Reserve. Its chair Jay Powell will on Wednesday unveil the US central bank’s decision on interest rates. The uncomfortable relationship between the president and ...

Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria. Medical affairs is evolving.